Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is N/A as of Tuesday, October 6, 2026.
GROSS MARGIN
N/A
Market Cap
$797.70M
Gross Margin
94.30%
TTM Avg
95.84%
3Y Avg
95.72%
5Y Avg
72.44%
Market Cap
$795.58M
Gross Margin
10.37%
TTM Avg
19.20%
3Y Avg
18.44%
5Y Avg
17.81%
Market Cap
$795.49M
Gross Margin
97.42%
TTM Avg
97.90%
3Y Avg
98.95%
5Y Avg
-3197.94%
Market Cap
$787.12M
Gross Margin
98.85%
TTM Avg
98.73%
3Y Avg
-10570.46%
5Y Avg
-10093.61%
Market Cap
$780.99M
Gross Margin
40.44%
TTM Avg
20.22%
3Y Avg
20.22%
5Y Avg
20.22%
Market Cap
$838.71M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apnimed, Inc. (APMD) | $807.61M | N/A | N/A | N/A | N/A |
| InMode Ltd. (INMD)vs › | $805.59M | 76.52% | 79.43% | 81.57% | 82.72% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $797.70M | 94.30% | 95.84% | 95.72% | 72.44% |
| Ardelyx, Inc. (ARDX)vs › | $817.67M | 93.96% | 87.19% | 88.05% | 90.06% |
| AdaptHealth Corp. (AHCO)vs › | $795.58M | 10.37% | 19.20% | 18.44% | 17.81% |
| Geron Corporation (GERN)vs › | $795.49M | 97.42% | 97.90% | 98.95% | -3197.94% |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $787.12M | 98.85% | 98.73% | -10570.46% | -10093.61% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $780.99M | 40.44% | 20.22% | 20.22% | 20.22% |
| Jade Biosciences, Inc. (JBIO)vs › | $838.71M | 0.00% | 0.00% | 0.00% | 0.00% |
| QuidelOrtho Corporation (QDEL)vs › | $841.20M | 44.60% | 46.45% | 50.53% | 59.76% |
Gross Margin
N/A
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
